99mtc-darping3
Recombinant proteinexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2022 (NCT05376644)
Timeline
No events for the selected filters.
Mechanism of action
Epidermal growth factor receptor and ErbB2 (HER1 and HER2) binding agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05376644 | N/A | May 1, 2022 | Russian Academy of Medical Sciences, Uppsala University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Russian Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Uppsala University | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1